Prelude Capital Management’s Tandem Diabetes Care TNDM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-18,754
| Closed | -$228K | – | 1551 |
|
|
2025
Q3 | $228K | Buy |
+18,754
| New | +$254K | 0.02% | 879 |
|
|
2025
Q2 | – | Sell |
-38,159
| Closed | -$731K | – | 1359 |
|
|
2025
Q1 | $731K | Sell |
38,159
-59,531
| -61% | -$1.74M | 0.06% | 390 |
|
|
2024
Q4 | $3.52M | Buy |
97,690
+29,580
| +43% | +$1M | 0.22% | 93 |
|
|
2024
Q3 | $2.89M | Buy |
68,110
+30,189
| +80% | +$1.28M | 0.17% | 146 |
|
|
2024
Q2 | $1.53M | Sell |
37,921
-38,109
| -50% | -$1.59M | 0.11% | 238 |
|
|
2024
Q1 | $2.69M | Buy |
76,030
+68,105
| +859% | +$1.82M | 0.14% | 162 |
|
|
2023
Q4 | $234K | Buy |
+7,925
| New | +$164K | 0.02% | 863 |
|
|
2023
Q2 | – | Sell |
-6,514
| Closed | -$265K | – | 1350 |
|
|
2023
Q1 | $265K | Sell |
6,514
-3,159
| -33% | -$131K | 0.02% | 701 |
|
|
2022
Q4 | $435K | Sell |
9,673
-5,544
| -36% | -$251K | 0.02% | 624 |
|
|
2022
Q3 | $728K | Buy |
15,217
+6,081
| +67% | +$333K | 0.03% | 520 |
|
|
2022
Q2 | $541K | Sell |
9,136
-7,101
| -44% | -$583K | 0.02% | 775 |
|
|
2022
Q1 | $1.89M | Buy |
16,237
+12,392
| +322% | +$1.45M | 0.05% | 361 |
|
|
2021
Q4 | $579K | Buy |
3,845
+326
| +9% | +$44K | 0.01% | 928 |
|
|
2021
Q3 | $420K | Sell |
3,519
-7,726
| -69% | -$851K | 0.01% | 984 |
|
|
2021
Q2 | $1.09M | Buy |
+11,245
| New | +$1M | 0.03% | 563 |
|
|
2020
Q3 | – | Sell |
-1,031
| Closed | -$102K | – | 2346 |
|
|
2020
Q2 | $102K | Buy |
+1,031
| New | +$82.3K | 0.01% | 953 |
|
|
2020
Q1 | – | Sell |
-4,696
| Closed | -$280K | – | 2026 |
|
|
2019
Q4 | $280K | Buy |
4,696
+4,502
| +2,321% | +$278K | 0.01% | 746 |
|
|
2019
Q3 | $11K | Buy |
194
+82
| +73% | +$5.23K | ﹤0.01% | 1485 |
|
|
2019
Q2 | $7K | Sell |
112
-10,938
| -99% | -$706K | ﹤0.01% | 1470 |
|
|
2019
Q1 | $702K | Sell |
11,050
-6,422
| -37% | -$337K | 0.04% | 413 |
|
|
2018
Q4 | $663K | Buy |
17,472
+16,391
| +1,516% | +$579K | 0.04% | 394 |
|
|
2018
Q3 | $46K | Sell |
1,081
-1,390
| -56% | -$48.5K | ﹤0.01% | 1152 |
|
|
2018
Q2 | $54K | Sell |
2,471
-6,369
| -72% | -$78.3K | ﹤0.01% | 1103 |
|
|
2018
Q1 | $44K | Buy |
8,840
+8,803
| +23,792% | +$28.4K | ﹤0.01% | 1124 |
|
|
2017
Q4 | $0 | Sell |
37
-40
| -52% | -$126 | ﹤0.01% | 1715 |
|
|
2017
Q3 | $1K | Buy |
+77
| New | +$487 | ﹤0.01% | 1570 |
|
|
2015
Q2 | – | Sell |
-80
| Closed | -$10K | – | 2036 |
|
|
2015
Q1 | $10K | Buy |
+80
| New | +$10.4K | ﹤0.01% | 1833 |
|
Other funds holding TNDM
SC
ACH
GKIM
PIM
Prelude Capital Management's TNDM Position: Q4 2025 in Review
Prelude Capital Management sold out of Tandem Diabetes Care (TNDM) in Q4 2025, closing a stake of 18,754 shares — an estimated $228K sold.
Prelude Capital Management first reported a position in TNDM in Q1 2015 and held it in 27 quarters. The position peaked at $3.52M in Q4 2024. 268 funds tracked by Wall St. Rank hold TNDM as of Q4 2025.
- Prelude Capital Management reported no remaining Tandem Diabetes Care position as of Q4 2025 after selling out during the quarter.
- Prelude Capital Management sold 18,754 Tandem Diabetes Care shares in Q4 2025, an estimated $228K.
- Prelude Capital Management first reported a position in Tandem Diabetes Care in Q1 2015 and held it in 27 quarters.
- Prelude Capital Management's Tandem Diabetes Care position peaked at $3.52M in Q4 2024.
- 268 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q4 2025.
Based on Prelude Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.